%0 Journal Article %A Heidi E Drummer %A Huy Van %A Ethan Klock %A Shuning Zheng %A Zihui Wei %A Irene Boo %A Rob J Center %A Fan Li %A Purnima Bhat %A Rosemary Ffrench %A Jillian SY Lau %A James McMahon %A Oliver Laeyendecker %A Reinaldo E. Fernandez %A Yukari C. Manabe %A Sabra L. Klein %A Thomas C. Quinn %A David A. Anderson %T Dimeric IgA is a specific biomarker of recent SARS-CoV-2 infection %D 2021 %R 10.1101/2021.06.28.21259671 %J medRxiv %P 2021.06.28.21259671 %X Current tests for SARS-CoV-2 antibodies (IgG, IgM, IgA) cannot differentiate recent and past infections. We describe a point of care, lateral flow assay for SARS-CoV-2 dIgA based on the highly selective binding of dIgA to a chimeric form of secretory component (CSC), that distinguishes dIgA from monomeric IgA. Detection of specific dIgA uses a complex of biotinylated SARS-CoV-2 receptor binding domain and streptavidin-colloidal gold. SARS-CoV-2-specific dIgA was measured both in 112 cross-sectional samples and a longitudinal panel of 362 plasma samples from 45 patients with PCR-confirmed SARS-CoV-2 infection, and 193 discrete pre-COVID-19 or PCR-negative patient samples. The assay demonstrated 100% sensitivity from 11 days post-symptom onset, and a specificity of 98.2%. With an estimated half-life of 6.3 days, dIgA provides a unique biomarker for the detection of recent SARS-CoV-2 infections with potential to enhance diagnosis and management of COVID-19 at point-of-care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. This study was supported by the COVID-19 Victorian Consortium grant from the Victorian Government; HV was supported by an APPRISE Research Fellowship from the National Health and Medical Research Council of Australia (NHMRC; 1116530). This study was supported in part by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA, and the Johns Hopkins COVID-19 Serology Center of Excellence (U54 CA260492, SLK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Alfred Human Research Ethics Committee and The Johns Hopkins University School of Medicine Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is presented in the manuscript. Data files can be obtained from Authors upon request. %U https://www.medrxiv.org/content/medrxiv/early/2021/07/01/2021.06.28.21259671.full.pdf